Answers are grounded in this paper and cite their sources.
Background : Diabetic patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) are at an elevated risk for perioperative morbidity and mortality. This risk is compounded by the profound neuroendocrine stress response and systemic inflammation induced by CPB, leading to severe insulin resistance, hyperglycemia, and hyperlactatemia. Intraoperative hyperlactatemia is a well-established surrogate marker for compromised tissue oxygen delivery, low cardiac output syndrome, metabolic derangements, higher inotropic need and poor postoperative outcomes. Objective : This narrative review explores the pathophysiological mechanisms underlying CPB-induced hyperlactatemia in diabetic patients and evaluates the metabolic and clinical effects of intraoperative tight glycemic control (TGC) on lactate clearance and production. Discussion : Lactate accumulation during CPB is biphasic, stemming from both microcirculatory hypoperfusion (Type A) and accelerated aerobic glycolysis driven by catecholamine surges (Type B). In the diabetic myocardium, glucose utilization is inherently impaired due to alterations in the phosphatidylinositol 3-kinase (PI3K) pathway and downregulation of glucose transporters. Exogenous insulin therapy, utilized in TGC protocols, actively modulates cellular metabolism by stimulating the pyruvate dehydrogenase (PDH) complex, shifting energy production from free fatty acid oxidation toward glucose oxidation. This metabolic shift reduces the cytosolic accumulation of pyruvate, thereby decreasing lactate production. While physiological evidence suggests that rigorous glycemic management attenuates intraoperative hyperlactatemia, the clinical application of strict TGC (80–110 mg/dL) is heavily scrutinized due to the devastating risks of masked intraoperative hypoglycemia. Conclusion : Intraoperative glycemic control favorably influences lactate kinetics in diabetic patients by optimizing oxidative phosphorylation and mitigating endothelial dysfunction. However, modern clinical practice favors protocolized, moderate glycemic targets (140–180 mg/dL) over strict TGC to safely balance metabolic optimization with the prevention of hypoglycemic events. Emerging technologies like continuous glucose monitoring (CGM) and closed-loop systems offer promising avenues for safer intraoperative metabolic management.
No takes yet. Share an insight, caveat, or question.
Kiran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: